## Contents

Preface ......................................................................................................................... v
Contributors ................................................................................................................. xi
Color Plates ....................................................................................................................... xv

### PART I: TRENDS IN PROSTATE CANCER SCREENING

1. Overview of US Prostate Cancer Trends in the Era of PSA Screening .................. 3
   *Ruth Etzioni, Roman Gulati, and Angela Mariotto*

2. Trends in Prostate Cancer Screening: Overview of the UK ................................ 15
   *Richard J. Bryant and Freddie C. Hamdy*

3. Trends in Prostate Cancer Screening: Canada ....................................................... 23
   *Robert K. Nam and Laurence H. Klotz*

4. Trends in Prostate Cancer Screening – Overview of Europe ............................... 35
   *Sanjai K. Addla and Bob Djavan*

### PART II: PROSTATE-SPECIFIC ANTIGEN

5. Evolution of Prostate-Specific Antigen for Screening ......................................... 51
   *Javier Hernandez and Edith Canby-Hagino*

6. The Performance Characteristics of Prostate-Specific Antigen for Prostate Cancer Screening .......................................................... 61
   *Ian M. Thompson, Jr. and Donna P. Ankerst*

7. The Performance of PSA for Predicting Prostate Cancer After a Prior Negative Prostate Biopsy ................................................................. 71
   *Catherine M. Tangen*

8. Subfractions and Derivatives of Total Prostate-Specific Antigen in the Early Detection of Prostate Cancer ......................................................... 79
   *Alexander Haese and Alan W. Partin*

9. PSA Velocity at Presentation as a Predictor of Prostate Cancer Aggressiveness .... 97
   *Jason A. Efstathiou and Anthony V. D’Amico*

### PART III: RISK ASSESSMENT FOR PROSTATE CANCER

10. Nomograms for Prostate Cancer .......................................................................... 117
    *Shahrokh F. Shariat and Michael W. Kattan*
PART I: DECISION AID CRITERIA AND ARTIFICIAL NEURAL NETWORKS FOR OPTIMIZING PROSTATE CANCER RISK PREDICTION

11 Decision Aid Criteria and Artificial Neural Networks for Optimizing Prostate Cancer Risk Prediction ...................................................... 181
   Felix K.-H. Chun and Pierre I. Karakiewicz

12 Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator .............................................................. 195
   Donna P. Ankerst and Ian M. Thompson

13 Integration of Risk Assessment in Prostate Cancer Screening .......................... 205
   Kadee E Thompson, Amanda Reed, and Dipen J Parekh

14 Family History of Prostate Cancer During Rapidly Increasing Incidence .......... 213
   Kari Hemminki and Justo Lorenzo Bermejo

PART IV: RECENT BIOMARKERS FOR PROSTATE CANCER

15 PSA Isoforms: [−2]proPSA Significant Adjunct to Free PSA ..................... 225
   Jeffrey E. Tam

16 PCA3 .......................................................... 233
   Jack Groskopf, Jack Schalken, and Harry Rittenhouse

17 Transcriptional Profiling of Prostate Cancer: Biomarker Identification and Clinical Applications ..................................................... 243
   Nigel Clegg and Peter S. Nelson

18 Biomarkers for Prostate Cancer Detection: Family-Based Linkage Analysis and Case-Control Association Studies .............................. 261
   Joke Beuten and Teresa L Johnson-Pais

19 GSTP1 Hypermethylation for Prostate Cancer Detection .......................... 279
   Rui Henrique and Carmen Jerónimo

20 EPCA and EPCA-2 as Potential Biomarkers for Prostate Cancer Detection ........ 289
   Eddy S. Leman and Robert H. Getzenberg

PART V: DESIGN AND METHODOLOGIC CONSIDERATIONS IN BIOMARKER STUDIES

21 Toward a Robust System for Biomarker Triage and Validation – EDRN Experience ................................................................. 297
   Ziding Feng, Jacob Kagan and Sudhir Srivastava

22 Statistical Evaluation of Markers and Risk Tools for Prostate Cancer Classification and Prediction .................................................. 307
   Yingye Zheng and Donna P. Ankerst

23 Pitfalls in Prostate Cancer Biomarker Evaluation Studies .......................... 319
   Donna P. Ankerst

PART VI: BUILDING UPON RECENTLY COMPLETED AND ONGOING PROSPECTIVE TRIALS

24 Prostate-Specific Antigen and Its Role on the Prostate Cancer Prevention Trial ........ 333
   Catherine M. Tangen and Phyllis J. Goodman
Prostate Cancer Screening
Second Edition
Pauler Ankerst, D.; Tangen, C.M.; Thompson, I.M. (Eds.)
2009, XVI, 397 p., Hardcover
A product of Humana Press